Click for best price
Lung Cancer Molecular Diagnostics Market Size, Share 2023
A molecular approach for diagnosing lung cancer
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Molecular Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Molecular Diagnostics. This report contains market size and forecasts of Lung Cancer Molecular Diagnostics in global, including the following market information:
Global Lung Cancer Molecular Diagnostics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Lung Cancer Molecular Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
PCR Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Lung Cancer Molecular Diagnostics include Foundationmedicine, Roche, Qiagen, Liferiver, Tellgen, Genetech, Gpmedical, Sansure and Amoydx, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Lung Cancer Molecular Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lung Cancer Molecular Diagnostics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Lung Cancer Molecular Diagnostics Market Segment Percentages, by Type, 2022 (%)
PCR
FISH
DNA Sequencing
Gene Chip
Global Lung Cancer Molecular Diagnostics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Lung Cancer Molecular Diagnostics Market Segment Percentages, by Application, 2022 (%)
Clinical Diagnosis
Drug Screening
Research
Global Lung Cancer Molecular Diagnostics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Lung Cancer Molecular Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Lung Cancer Molecular Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Lung Cancer Molecular Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Foundationmedicine
Roche
Qiagen
Liferiver
Tellgen
Genetech
Gpmedical
Sansure
Amoydx
Mole
Annoroad
Outline of Major Chapters:
Chapter 1: Introduces the definition of Lung Cancer Molecular Diagnostics, market overview.
Chapter 2: Global Lung Cancer Molecular Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Lung Cancer Molecular Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Lung Cancer Molecular Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Lung Cancer Molecular Diagnostics Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Lung Cancer Molecular Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Lung Cancer Molecular Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Lung Cancer Molecular Diagnostics Overall Market Size
2.1 Global Lung Cancer Molecular Diagnostics Market Size: 2022 VS 2030
2.2 Global Lung Cancer Molecular Diagnostics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Lung Cancer Molecular Diagnostics Players in Global Market
3.2 Top Global Lung Cancer Molecular Diagnostics Companies Ranked by Revenue
3.3 Global Lung Cancer Molecular Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Lung Cancer Molecular Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Lung Cancer Molecular Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Lung Cancer Molecular Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Lung Cancer Molecular Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Lung Cancer Molecular Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Lung Cancer Molecular Diagnostics Market Size Markets, 2022 & 2030
4.1.2 PCR
4.1.3 FISH
4.1.4 DNA Sequencing
4.1.5 Gene Chip
4.2 By Type - Global Lung Cancer Molecular Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Lung Cancer Molecular Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Lung Cancer Molecular Diagnostics Revenue, 2024-2030
4.2.3 By Type - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Lung Cancer Molecular Diagnostics Market Size, 2022 & 2030
5.1.2 Clinical Diagnosis
5.1.3 Drug Screening
5.1.4 Research
5.2 By Application - Global Lung Cancer Molecular Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Lung Cancer Molecular Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Lung Cancer Molecular Diagnostics Revenue, 2024-2030
5.2.3 By Application - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Lung Cancer Molecular Diagnostics Market Size, 2022 & 2030
6.2 By Region - Global Lung Cancer Molecular Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Lung Cancer Molecular Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Lung Cancer Molecular Diagnostics Revenue, 2024-2030
6.2.3 By Region - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Lung Cancer Molecular Diagnostics Revenue, 2018-2030
6.3.2 US Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.3.3 Canada Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.3.4 Mexico Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Lung Cancer Molecular Diagnostics Revenue, 2018-2030
6.4.2 Germany Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.4.3 France Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.4.4 U.K. Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.4.5 Italy Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.4.6 Russia Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.4.7 Nordic Countries Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.4.8 Benelux Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Lung Cancer Molecular Diagnostics Revenue, 2018-2030
6.5.2 China Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.5.3 Japan Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.5.4 South Korea Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.5.5 Southeast Asia Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.5.6 India Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Lung Cancer Molecular Diagnostics Revenue, 2018-2030
6.6.2 Brazil Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.6.3 Argentina Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Lung Cancer Molecular Diagnostics Revenue, 2018-2030
6.7.2 Turkey Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.7.3 Israel Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.7.4 Saudi Arabia Lung Cancer Molecular Diagnostics Market Size, 2018-2030
6.7.5 UAE Lung Cancer Molecular Diagnostics Market Size, 2018-2030
7 Lung Cancer Molecular Diagnostics Companies Profiles
7.1 Foundationmedicine
7.1.1 Foundationmedicine Company Summary
7.1.2 Foundationmedicine Business Overview
7.1.3 Foundationmedicine Lung Cancer Molecular Diagnostics Major Product Offerings
7.1.4 Foundationmedicine Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Foundationmedicine Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Lung Cancer Molecular Diagnostics Major Product Offerings
7.2.4 Roche Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Qiagen
7.3.1 Qiagen Company Summary
7.3.2 Qiagen Business Overview
7.3.3 Qiagen Lung Cancer Molecular Diagnostics Major Product Offerings
7.3.4 Qiagen Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Qiagen Key News & Latest Developments
7.4 Liferiver
7.4.1 Liferiver Company Summary
7.4.2 Liferiver Business Overview
7.4.3 Liferiver Lung Cancer Molecular Diagnostics Major Product Offerings
7.4.4 Liferiver Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Liferiver Key News & Latest Developments
7.5 Tellgen
7.5.1 Tellgen Company Summary
7.5.2 Tellgen Business Overview
7.5.3 Tellgen Lung Cancer Molecular Diagnostics Major Product Offerings
7.5.4 Tellgen Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Tellgen Key News & Latest Developments
7.6 Genetech
7.6.1 Genetech Company Summary
7.6.2 Genetech Business Overview
7.6.3 Genetech Lung Cancer Molecular Diagnostics Major Product Offerings
7.6.4 Genetech Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.6.5 Genetech Key News & Latest Developments
7.7 Gpmedical
7.7.1 Gpmedical Company Summary
7.7.2 Gpmedical Business Overview
7.7.3 Gpmedical Lung Cancer Molecular Diagnostics Major Product Offerings
7.7.4 Gpmedical Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Gpmedical Key News & Latest Developments
7.8 Sansure
7.8.1 Sansure Company Summary
7.8.2 Sansure Business Overview
7.8.3 Sansure Lung Cancer Molecular Diagnostics Major Product Offerings
7.8.4 Sansure Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Sansure Key News & Latest Developments
7.9 Amoydx
7.9.1 Amoydx Company Summary
7.9.2 Amoydx Business Overview
7.9.3 Amoydx Lung Cancer Molecular Diagnostics Major Product Offerings
7.9.4 Amoydx Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Amoydx Key News & Latest Developments
7.10 Mole
7.10.1 Mole Company Summary
7.10.2 Mole Business Overview
7.10.3 Mole Lung Cancer Molecular Diagnostics Major Product Offerings
7.10.4 Mole Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.10.5 Mole Key News & Latest Developments
7.11 Annoroad
7.11.1 Annoroad Company Summary
7.11.2 Annoroad Business Overview
7.11.3 Annoroad Lung Cancer Molecular Diagnostics Major Product Offerings
7.11.4 Annoroad Lung Cancer Molecular Diagnostics Revenue in Global Market (2018-2023)
7.11.5 Annoroad Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Lung Cancer Molecular Diagnostics Market Opportunities & Trends in Global Market
Table 2. Lung Cancer Molecular Diagnostics Market Drivers in Global Market
Table 3. Lung Cancer Molecular Diagnostics Market Restraints in Global Market
Table 4. Key Players of Lung Cancer Molecular Diagnostics in Global Market
Table 5. Top Lung Cancer Molecular Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Lung Cancer Molecular Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Lung Cancer Molecular Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Lung Cancer Molecular Diagnostics Product Type
Table 9. List of Global Tier 1 Lung Cancer Molecular Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Lung Cancer Molecular Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Lung Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Lung Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Lung Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Lung Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Lung Cancer Molecular Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Lung Cancer Molecular Diagnostics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2024-2030
Table 30. Foundationmedicine Company Summary
Table 31. Foundationmedicine Lung Cancer Molecular Diagnostics Product Offerings
Table 32. Foundationmedicine Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Foundationmedicine Key News & Latest Developments
Table 34. Roche Company Summary
Table 35. Roche Lung Cancer Molecular Diagnostics Product Offerings
Table 36. Roche Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Roche Key News & Latest Developments
Table 38. Qiagen Company Summary
Table 39. Qiagen Lung Cancer Molecular Diagnostics Product Offerings
Table 40. Qiagen Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. Qiagen Key News & Latest Developments
Table 42. Liferiver Company Summary
Table 43. Liferiver Lung Cancer Molecular Diagnostics Product Offerings
Table 44. Liferiver Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Liferiver Key News & Latest Developments
Table 46. Tellgen Company Summary
Table 47. Tellgen Lung Cancer Molecular Diagnostics Product Offerings
Table 48. Tellgen Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. Tellgen Key News & Latest Developments
Table 50. Genetech Company Summary
Table 51. Genetech Lung Cancer Molecular Diagnostics Product Offerings
Table 52. Genetech Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. Genetech Key News & Latest Developments
Table 54. Gpmedical Company Summary
Table 55. Gpmedical Lung Cancer Molecular Diagnostics Product Offerings
Table 56. Gpmedical Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. Gpmedical Key News & Latest Developments
Table 58. Sansure Company Summary
Table 59. Sansure Lung Cancer Molecular Diagnostics Product Offerings
Table 60. Sansure Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Sansure Key News & Latest Developments
Table 62. Amoydx Company Summary
Table 63. Amoydx Lung Cancer Molecular Diagnostics Product Offerings
Table 64. Amoydx Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. Amoydx Key News & Latest Developments
Table 66. Mole Company Summary
Table 67. Mole Lung Cancer Molecular Diagnostics Product Offerings
Table 68. Mole Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. Mole Key News & Latest Developments
Table 70. Annoroad Company Summary
Table 71. Annoroad Lung Cancer Molecular Diagnostics Product Offerings
Table 72. Annoroad Lung Cancer Molecular Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 73. Annoroad Key News & Latest Developments
List of Figures
Figure 1. Lung Cancer Molecular Diagnostics Segment by Type in 2022
Figure 2. Lung Cancer Molecular Diagnostics Segment by Application in 2022
Figure 3. Global Lung Cancer Molecular Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Lung Cancer Molecular Diagnostics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Lung Cancer Molecular Diagnostics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Lung Cancer Molecular Diagnostics Revenue in 2022
Figure 8. By Type - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 16. US Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 20. Germany Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 21. France Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 28. China Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 32. India Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 34. Brazil Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Lung Cancer Molecular Diagnostics Revenue Market Share, 2018-2030
Figure 37. Turkey Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Lung Cancer Molecular Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 41. Foundationmedicine Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Roche Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Qiagen Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Liferiver Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Tellgen Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Genetech Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Gpmedical Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sansure Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Amoydx Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Mole Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Annoroad Lung Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
